Lipocine Inc - LPCN Net Assets per Single Share

Graphic logo of Lipocine Inc. (LPCN)

High clinic costs and regulatory risks create stringent barriers to entry in the sector. The current book value per share of Lipocine Inc. (LPCN) demonstrates capital resilience, while the 2.66 mark indicates the level of the financial base. Leadership in oral hormone delivery via Lip'ral neutralizes threats, and yields from patent licenses support the company's operational activity.

Lipocine Inc (LPCN): Share Book Value from 07/04/2022 to 10/27/2026

lipocine.com - analytical breakdowns and key metrics (LPCN)

- price and consensus price forecast:
Stock Price Lipocine Corp|LPCN - Consensus Target
- market capitalization data:
Market Value Lipocine Inc.|LPCN - Business Value
- book capitalization data:
Net Assets per Single Share Lipocine|LPCN - Net Asset Value|Market Capitalization to Book Value Ratio lipocine.com|LPCN - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Lipocine Inc.|LPCN - Long-Term Debt to Capital|Short-Term Debt to Equity Lipocine|LPCN - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Lipocine Inc.
Fundamental company valuation:Lipocine Corp - LPCN
Manufactured products of Lipocine

Book value per share reflects the portion of net assets attributable to a single security, serving as a measure of the company's intrinsic value after deducting all liabilities. For Lipocine Inc. (LPCN), the book value per share curve demonstrates the capitalization efficiency of investments in Lip'ral IT platforms, confirming capital preservation during the automation of drug development and protecting the investor from default risks.

Competitors of Lipocine Inc. (LPCN)

ASND: Book Value per Share|MDGL: Accounting Value per Share|Net Assets per Single Share Corcept Therapeutics|RYTM (rhythmtx.com) - Equity per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com (RZLT)|Lexicon Pharmaceuticals, Inc. (LXRX) - Accounting Value per Share|Accounting Value of a Share MBX (MBX Biosciences, Inc.)|Altimmune Corp - Net Assets per Single Share|Accounting Value per Share Aardvark Pharma AARD|SGMT (Sagimet Biosciences) - Book Value per Share|bioagelabs.com (BIOA) - Net Asset Value per Share|BMEA - Accounting Value per Share|Quince Therapeutics, Inc. (QNCX) - Book Price of a Share|GUTS (Fractyl) - Book Value per Share|Book Value per Share vTv Therapeutics Inc|Book Value per Share Agape ATP Corporation (ATPC)|Net Assets per Single Share PLUR (pluri-biotech.com)|SYBX: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS